Lexicon Pharmaceuticals, Inc.
LXRX
$0.53
-$0.0019-0.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -13.15% | -37.08% | -54.61% | -75.34% | -73.74% |
| Total Depreciation and Amortization | -3.61% | 9.02% | 24.41% | 36.28% | 29.74% |
| Total Amortization of Deferred Charges | 4.00% | 37.38% | 107.09% | 106.52% | 139.41% |
| Total Other Non-Cash Items | -51.09% | -28.19% | -46.34% | -10.44% | -11.18% |
| Change in Net Operating Assets | 435.46% | -114.88% | -169.23% | -2,349.54% | 561.44% |
| Cash from Operations | -10.43% | -56.36% | -76.85% | -91.06% | -82.21% |
| Capital Expenditure | -119.36% | 67.54% | 79.66% | 85.18% | 64.56% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 71.00% | 78.11% | 3.74% | -224.12% | 29.07% |
| Cash from Investing | 69.21% | 77.88% | 4.81% | -215.63% | 29.73% |
| Total Debt Issued | -- | -100.00% | -100.00% | 102.11% | 2.24% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.94% | -99.94% | -99.96% | 47.58% | 47.49% |
| Repurchase of Common Stock | -69.57% | -57.56% | -118.83% | -118.83% | -11.65% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 26.81% | 12.02% | -22.12% | 262.54% | 32.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 285.05% | 488.74% | -182.47% | 310.31% | -34.76% |